Cargando…

Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction

BACKGROUND: Stereotactic body radiation therapy (SBRT) delivers high doses of radiation to the prostate while minimizing radiation to the adjacent critical organs. Large fraction sizes may increase urinary morbidity due to unavoidable treatment of the prostatic urethra. This study reports rates of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Repka, Michael C., Guleria, Shan, Cyr, Robyn A., Yung, Thomas M., Koneru, Harsha, Chen, Leonard N., Lei, Siyuan, Collins, Brian T., Krishnan, Pranay, Suy, Simeng, Dritschilo, Anatoly, Lynch, John, Collins, Sean P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870496/ https://www.ncbi.nlm.nih.gov/pubmed/27242962 http://dx.doi.org/10.3389/fonc.2016.00122

Ejemplares similares

Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design
por: Paydar, Ima, et al.
Publicado: (2016)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging
por: Paydar, Ima, et al.
Publicado: (2015)

Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
por: Gurka, Marie K, et al.
Publicado: (2015)

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3))
por: Janowski, Einsley, et al.
Publicado: (2014)

Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer
por: Rana, Zaker, et al.
Publicado: (2014)

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
por: Kataria, Shaan, et al.
Publicado: (2017)

The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Koneru, Harsha, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
por: Woo, Jennifer Ai-Lian, et al.
Publicado: (2015)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
por: Mercado, Catherine, et al.
Publicado: (2016)

Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer
por: Sood, Sumit, et al.
Publicado: (2013)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity
por: Paydar, Ima, et al.
Publicado: (2017)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer
por: Bhattasali, Onita, et al.
Publicado: (2014)

Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer
por: Arscott, W Tristram, et al.
Publicado: (2014)

Proctitis following stereotactic body radiation therapy for prostate cancer
por: Joh, Daniel Y, et al.
Publicado: (2014)

Clinical Characteristics and Management of Late Urinary Symptom Flare Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Woo, Jennifer A., et al.
Publicado: (2014)

Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
por: Chen, Leonard N, et al.
Publicado: (2014)

Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
por: Chen, Leonard N, et al.
Publicado: (2013)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy
por: Lei, Siyuan, et al.
Publicado: (2011)

Potency preservation following stereotactic body radiation therapy for prostate cancer
por: Obayomi-Davies, Olusola, et al.
Publicado: (2013)

Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk
por: Repka, Michael C., et al.
Publicado: (2018)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
por: Pepin, Abigail, et al.
Publicado: (2020)

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer
por: Danner, Malika, et al.
Publicado: (2017)

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
por: Aghdam, Nima, et al.
Publicado: (2020)

Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Pepin, Abigail, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine Cancer
por: Aghdam, Nima, et al.
Publicado: (2020)

Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors
por: Kress, Marie-Adele S, et al.
Publicado: (2012)

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
por: Pepin, Abigail, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
por: Aghdam, Nima, et al.
Publicado: (2020)

Stereotactic Body Radiation Therapy for Liver Metastases from Colorectal Cancer: Analysis of Safety, Feasibility, and Early Outcomes
por: Kress, Marie-Adele S., et al.
Publicado: (2012)

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT)
por: Shah, Sarthak, et al.
Publicado: (2023)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

CyberKnife for hilar lung tumors: report of clinical response and toxicity
por: Unger, Keith, et al.
Publicado: (2010)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Shah, Sarthak, et al.
Publicado: (2021)

Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation
por: Repka, Michael C., et al.
Publicado: (2017)

Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal–Prostate Interface and Spare the Rectum: A Case Report
por: Conroy, Dylan, et al.
Publicado: (2021)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
por: Carrasquilla, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v2d75abks6up84a2eupm1fl1kn